drugset

drugset / Trial / NCT00549978

Safety and Pharmacokinetics of Probucol and Cilostazol

NCT00549978 ↗

Phase 4 Completed 32 enrolled Korea Otsuka Pharmaceutical Co., Ltd. Otsuka Pharmaceutical Co., Ltd. · collab

RandomizedCrossoverOpen-labelTreatment

Summary

to investigate the safety and pharmacokinetics, in healthy adult male subjects

Timeline

Start: 2007-10
Primary completion: 2008-05
Completion: 2008-08

Publications

Kim KP, Kim BH, Lim KS, Kim TE, Shin SG, Jang IJ, Yu KS. Potential interactions between cilostazol and probucol: a two-part, single-dose, open-label study in healthy Korean male volunteers. Clin Ther. 2009 Oct;31(10):2098-106. doi: 10.1016/j.clinthera.2009.10.005.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Cilostazol	Small molecule	100 mg	—
Subject	Probucol	Small molecule	250 mg	—
Subject	Probucol	Small molecule	500 mg	—

Indications

No indication recorded.